Publications by authors named "Emmanuelle Ferrant"

Claim this Profile
A
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, Krish Patel, Emmanuelle Ferrant

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Nicolas Gazeau, David Beauvais, Rémi Tilmont, Micha Srour, Emmanuelle Ferrant

Leukemia· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ Mutation: SEQUOIA Arm D Results.
Mazyar Shadman, Talha Munir, Shuo Ma, Masa Lasica, Monica Tani, Emmanuelle Ferrant

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.
Lucile Bussot, Stéphanie Poulain, Morgane Nudel Ortmans, Frédéric Davi, Damien Roos-Weil, Emmanuelle Ferrant

Leukemia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Emmanuelle Ferrant

Leukemia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.
Pierre Sesques, Lionel Karlin, Emmanuel Massy, Alizée Maarek, Guillaume Aussedat, Emmanuelle Ferrant

Front Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy.
Tadeusz Robak, Michael Doubek, Emmanuelle Ferrant, Joris Diels, Liva Andersone

Curr Med Res Opin· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.
Romain Guièze, Loïc Ysebaert, Damien Roos-Weil, Luc-Mathieu Fornecker, Emmanuelle Ferrant

Nat Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.
Caroline Le Lan, Aurélien Belot, Camille Golfier, Bérénice Audin, Pierre Sesques, Emmanuelle Ferrant

Hematol Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Emmanuelle Ferrant

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of a cohort of 41 B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).
Caroline Algrin, Louis Pérol, Elise Chapiro, Lucile Baseggio, Karim Maloum, Emmanuelle Ferrant

Haematologica· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-CLL, a New Next-Generation Sequencing-Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid Leukemia.
Estelle Bourbon, Kaddour Chabane, Isabelle Mosnier, Anne Bouvard, Florian Thonier, Emmanuelle Ferrant

J Mol Diagn· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma.
Estelle Bourbon, Pierre Sesques, Morgane Gossez, Jérémie Tordo, Emmanuelle Ferrant

Blood Adv· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas.
Clara Sortais, Stéphanie Cordeil, Estelle Bourbon, Maryam Idlhaj, Emmanuelle Ferrant

Leuk Lymphoma· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Emmanuelle Ferrant

Leukemia· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
Guillaume Aussedat, Delphine Maucort-Boulch, Philippe Rey, Violaine Safar, Lionel Karlin, Emmanuelle Ferrant

Leuk Lymphoma· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.
Pierre Sesques, Emmanuel Bachy, Emmanuelle Ferrant, Violaine Safar, Morgane Gossez

Cancer Cell· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal-storing histiocytosis and Bing-Neel-like syndrome revealing a small B-cell lymphoma with plasmacytic differentiation, presumed to be a marginal zone lymphoma.
Hippolyte Lequain, Mathieu Gerfaud-Valentin, Juliette Fontaine, Emmanuelle Ferrant, Pierre Grumet

Clin Case Rep· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Pierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, Violaine Safar, Florent Wallet

Clin Nucl Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified.
Estelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, Claire Mauduit, Pierre Sesques, Emmanuelle Ferrant

Blood Adv· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Pierre Sesques, Emmanuelle Ferrant, Violaine Safar, Florent Wallet, Jérémie Tordo

Am J Hematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia.
Sarah Huet, Anne Bouvard, Emmanuelle Ferrant, Isabelle Mosnier, Kaddour Chabane

Leukemia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
Loic Ysebaert, Anne Quinquenel, Fontané Bijou, Emmanuelle Ferrant, Anne-Sophie Michallet

Eur J Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Gilles Salles, Pierre Sesques, Emmanuelle Ferrant, Violaine Safar, Hervé Ghesquieres

Bull Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes.
Lauriane Filliatre-Clement, Delphine Maucort-Boulch, Estelle Bourbon, Lionel Karlin, Violaine Safar, Emmanuelle Ferrant

Hematol Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis